Zepp Health Corporation
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -73.5% | +60.8% | +121.4% | +50.6% | +20.2% | +5.8% | -20.5% | -16.2% | +506.9% | +2.4% | |
| – | -76.2% | +59.2% | +122.0% | +44.2% | +17.1% | -16.5% | -30.9% | -25.6% | +479.6% | +11.8% | |
| – | -89.8% | +155.1% | +289.2% | +16.6% | +34.3% | -31.9% | -40.8% | +0.3% | +475.3% | -2.3% | |
| – | -89.2% | +149.7% | +313.5% | +6.9% | +34.5% | -31.5% | -39.7% | +0.4% | +459.9% | -3.2% | |
| – | -65.1% | +37.2% | +17.7% | +106.1% | -18.1% | -12.8% | -26.6% | -34.6% | +604.6% | -10.9% | |
| – | -69.0% | +40.5% | +92.6% | +70.5% | +44.8% | +5.9% | -25.3% | -42.4% | +388.2% | +22.7% | |
| – | +269.1% | +166.2% | +39.3% | +332.1% | +59.4% | -12.1% | – | – | – | – | |
| – | – | – | -0.4% | -6.2% | +1,022.7% | +0.2% | -0.7% | +0.7% | +629.7% | -4.2% | |
| – | – | +366.0% | +1,088.7% | +26.3% | +80.3% | -4.2% | -16.5% | -44.4% | +424.4% | +83.9% | |
| – | -83.4% | +49.4% | +62.5% | +75.3% | +24.9% | +1.9% | -24.8% | -23.9% | +611.9% | +21.7% | |
| – | -67.1% | +47.6% | +57.5% | +69.6% | +18.4% | -20.8% | -28.8% | -35.4% | +819.1% | +40.7% | |
| – | -91.2% | +197.1% | +10.0% | -15.7% | +1,582.9% | +2.3% | +68.4% | -50.1% | +954.9% | +53.0% | |
| – | -70.1% | +44.2% | +49.7% | +76.4% | +3.9% | -30.7% | -68.2% | -43.3% | +899.6% | +51.5% | |
| – | – | – | – | – | – | +1,111.4% | -5.9% | +24.5% | -91.2% | -21.0% | |
| – | – | +81.4% | +213.4% | +29.6% | +16.3% | +9.8% | -16.0% | -8.8% | +423.2% | -18.3% | |
| – | – | – | +158.1% | +151.3% | +32.6% | +15.1% | -31.9% | -23.1% | +100.1% | -138.3% | |
| – | -75.0% | +0.0% | -5.3% | +14.8% | +0.7% | +1.5% | -6.8% | -1.3% | +6.5% | -93.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.